J&J Cancer Drug Zytiga Has New Competition

Jan 30, 2014

Ny Times

New study results for prostate cancer drug Xtandi showed that the drug prolonged lives and delayed tumor progression when used before chemotherapy, bringing competition to Johnson & Johnson’s blockbuster drug, Zytiga.

Xtandi, developed by Medivation and Astellas Pharma, was approved in 2012 as a treatment for men with metastatic prostate cancer who had already undergone chemotherapy. The new study showed that the drug is also effective when used before chemotherapy. J&J's Zytiga is also approved for use both before and after chemotherapy.

Read the Ny Times article